Acasti Pharma Inc. Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Note 14 - Capital and Other Components of Equity - Assumptions (Details)

Note 14 - Capital and Other Components of Equity - Assumptions (Details)				1 Months Ended	12 Months Ended
	May 09, 2018 $ / shares	Dec. 27, 2017 USD ($) $ / shares	Feb. 21, 2017 CAD ($) $ / shares	May 31, 2018 CAD ($) $ / shares	Mar. 31, 2019 $ / shares
Statement Line Items [Line Items]
Exercise price, warrants issued \| (per share)	$ 1.31	$ 1.2625	$ 2.15
May 2018 public offering warrants 2018 [member]
Statement Line Items [Line Items]
Exercise price, warrants issued \| $ / shares				$ 1.31	$ 1.31
Share price				$ 0.82
Risk-free interest				2.21%
Estimated life (in years) (Year)				5 years
Expected volatility				87.40%
Warrants issued to broker in May 2018 public offering [Member]
Statement Line Items [Line Items]
Exercise price, warrants issued \| $ / shares				$ 1.05
Share price				$ 0.81
Risk-free interest				2.20%
Estimated life (in years) (Year)				5 years
Expected volatility				87.40%
Public offering warrants in 2017 [member]
Statement Line Items [Line Items]
Exercise price, warrants issued \| $ / shares		$ 1.26
Share price		$ 0.97
Risk-free interest		2.22%
Estimated life (in years) (Year)		5 years
Expected volatility		93.52%
Warrants issued to broker in December 2017 public offering [Member]
Statement Line Items [Line Items]
Exercise price, warrants issued \| $ / shares		$ 1.2625
Share price		$ 0.97
Risk-free interest		2.22%
Estimated life (in years) (Year)		5 years
Expected volatility		93.52%
Warrants issued to broker in February 2017 public offering [member]
Statement Line Items [Line Items]
Exercise price, warrants issued \| $ / shares			$ 2.15
Share price			$ 1.70
Risk-free interest			0.79%
Estimated life (in years) (Year)			1 year
Expected volatility			112.09%
Dividend